Arrowstreet Capital, Limited Partnership Clovis Oncology, Inc. Transaction History

Arrowstreet Capital, Limited Partnership

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2020 May 15, 2020	SELL	$3.77 - $11.0 $899,156 - $2.62 Million	-238,503 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$3.0 - $16.43 $715,509 - $3.92 Million	238,503 New	238,503 $2.49 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.